McGroddy-Goetz Kathleen
Known title: DirectorCIK: 0001814371
McGroddy-Goetz Kathleen's purchase track record
McGroddy-Goetz Kathleen has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/15/2023 | TNDM | $21K | +31.6% | +31.6% | +15.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TNDM | ▲ Buy | Option Exercise | 8,759 | $0 | 5/21/2026 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 4,387 | $91K | 5/22/2025 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 4,434 | $229K | 5/24/2024 | View on chart |
| TNDM | ▲ Buy | Open Market | 1,000 | $21K | 9/15/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 1,220 | $0 | 6/8/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 2,757 | $0 | 5/25/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 1,220 | $0 | 6/8/2022 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 2,021 | $0 | 5/18/2022 | View on chart |
| TNDM | ▼ Sell | Open Market | 405 | $43K | 3/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating
Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating. Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.